taurolidine/heparin

REMS

To reduce the incidence of catheter-related bloodstream infections in patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter.

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Known heparin-induced thrombocytopenia;
Known hypersensitivity to taurolidine, heparin, the citrate excipient, or pork products.

Use Cautiously in:

Pedi: Safety and effectiveness not established in children.

Adv. Reactions/Side Effects ⬆ ⬇

GI: nausea, vomiting

Hemat: BLEEDING, HEPARIN-INDUCED THROMBOCYTOPENIA

MS: musculoskeletal chest pain

Neuro: dizziness

Misc: HD catheter malfunction, loss of catheter patency, hypersensitivity reactions

Interactions ⬆ ⬇

Drug-drug:

None reported.

Availability ⬆ ⬇

Catheter lock solution: taurolidine 13.5 mg/heparin 1000 units per mL

Route/Dosage ⬆ ⬇

Not intended for systemic administration or for use as a catheter lock flush.

Intracatheter(Adults ): Instill a sufficient volume of catheter lock solution (containing heparin 1000 units/mL and taurolidine 13.5 mg/mL) into each HD catheter lumen at the conclusion of each HD session; prior to initiation of the next HD session, aspirate and discard solution from the catheter.

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Taurolidine: Causes damage to microbial cell walls and inhibits adherence of microorganisms to biological surfaces; Heparin: Potentiates the inhibitory effect of antithrombin on factor Xa and thrombin.

Therapeutic effects:

Reduction in incidence of catheter-related bloodstream infections.

Classifications ⬆ ⬇

Therapeutic Classification: anti-infectives, anticoagulants

Pharmacologic Classification: antithrombotics

Pharmacokinetics ⬆ ⬇

Taurolidine

Absorption: Intracatheter administration allows for local action; not systemically absorbed.

Distribution: Not systemically absorbed.

Metabolism/Excretion: Not systemically absorbed.

Half-Life: Unknown.

Heparin